Kymera Therapeutics, Inc.
KYMR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815442
In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 276 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Kymera Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 5 insiders, $33.5M in total
- Insiders trading
- 5
- Net value
- −$33.5M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Kymera Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Adams Brian | Chief Legal Officer | 50,254 | Sep 4, 2026 | 2 |
| Rooney Terence | Chief Medical Officer | 38,000 | Jul 27, 2026 | 1 |
| Mainolfi Nello | Chief Executive Officer | 666,568 | Jul 7, 2026 | 10 |
| Jacobs Bruce N. | Chief Financial Officer | 244,883 | Jul 2, 2026 | 4 |
| Goodman Noah | Chief Business Officer | 47,179 | Jul 2, 2026 | 6 |
| Booth Bruce | Director | 462,856Indirect | Jul 2, 2026 | 12 |
| Biotechnology Value Fund L P | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| BVF Partners L P | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| BVF Inc | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| Biotechnology Value Fund II LP | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| Lampert Mark N | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| Biotechnology Value Trading Fund OS LP | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| BVF Partners OS Ltd. | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| BVF I GP LLC | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| BVF II GP LLC | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| BVF GP Holdings LLC | Director, Other: See Remarks and Footnotes | 78,787Indirect | Jun 26, 2026 | 2 |
| Baker Julian | Director, 10% Owner | 7,955,916Indirect | Jun 25, 2026 | 2 |
| Baker Felix | Director, 10% Owner | 7,955,916Indirect | Jun 25, 2026 | 2 |
| Baker Bros. Advisors LP | Director, 10% Owner | 7,955,916Indirect | Jun 25, 2026 | 2 |
| Baker Brothers Life Sciences LP | Director, 10% Owner | 7,955,916Indirect | Jun 25, 2026 | 2 |
| 667, L.P. | Director, 10% Owner | 7,955,916Indirect | Jun 25, 2026 | 2 |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | 7,955,916Indirect | Jun 25, 2026 | 2 |
| Maraganore John | Director | – | Jun 25, 2026 | 1 |
| Sandor Victor | Director | – | Jun 25, 2026 | 1 |
| Albers Jeffrey W. | Director | 0 | Jun 25, 2026 | 3 |
| Esposito Pamela | Director | 1,000 | Jun 25, 2026 | 6 |
| Ridloff Elena | Director | 0 | Jun 25, 2026 | 3 |
| Hrustanovic Gorjan | Director | – | Jun 25, 2026 | 1 |
| Chadwick Jeremy G | Chief Operating Officer | 44,018 | May 27, 2026 | 7 |
| Gollob Jared | Chief Medical Officer | 117,134 | Mar 4, 2026 | 4 |
| Chiniara Ellen | Chief Legal Officer | 80,085 | Mar 3, 2025 | 0 |
| Morgan Leigh | Director | – | Jun 20, 2024 | 0 |
| Horobin Joanna | Director | 0 | Jun 7, 2024 | 0 |
| Atlas Venture Fund X, L.P. | 10% Owner | 828,830Indirect | Mar 13, 2024 | 0 |
| Atlas Venture Associates X, LLC | 10% Owner | 828,830Indirect | Mar 13, 2024 | 0 |
| Atlas Venture Associates X, L.P. | 10% Owner | 828,830Indirect | Mar 13, 2024 | 0 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 828,830Indirect | Mar 13, 2024 | 0 |
| Atlas Venture Associates Opportunity I, L.P. | 10% Owner | 828,830Indirect | Mar 13, 2024 | 0 |
| Atlas Venture Associates Opportunity I, LLC | 10% Owner | 828,830Indirect | Mar 13, 2024 | 0 |
| Caughey Elaine | Chief Business Officer | 18,986 | Mar 3, 2023 | 0 |
| Nicholson Donald William | Director | – | Jun 16, 2022 | 0 |
| Chesworth Richard | Chief Scientific Officer | 0 | Aug 27, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 6, 2021 (view filing)6:40 PM ET | Jul 1 | 5 days | BVF Partners L P and 9 othersDirector, Other: See Remarks | PPurchaseCommon Stock, $0.0001 par value | +544.2K | $47.00 | +$25.6M | New position208.5K after | 3 lots |
| Jul 9, 2021 (view filing) | Jul 8 | 1 day | Mainolfi NelloChief Executive Officer | SSale | −48.0K | $49.70 | −$2.39M | −9.6%452.2K after | 4 lots |
| Jul 28, 2021 (view filing) | Jul 26-28 | 2 days | Mainolfi NelloChief Executive Officer | SSale | −12.9K | $60.15 | −$774.7K | −2.8%452.2K after | 2 lots |
| Aug 2, 2021 (view filing) | Jul 29-Aug 2 | 4 days | Mainolfi NelloChief Executive Officer | SSale | −30.4K | $60.25 | −$1.83M | −6.3%452.2K after | 5 lots |
| Aug 5, 2021 (view filing) | Aug 3-4 | 2 days | Mainolfi NelloChief Executive Officer | SSale | −6.71K | $60.06 | −$402.8K | −1.5%452.2K after | 2 lots |
| Aug 12, 2021 (view filing) | Aug 11 | 1 day | Booth BruceDirector | SSale | −242.1K | $61.00 | −$14.8M | −100.0%0 after | |
| Aug 12, 2021 (view filing)10:42 AM ET | Aug 11 | 1 day | Atlas Venture Associates X, LLC and 1 other10% Owner | SSale | −242.1K | $61.00 | −$14.8M | −100.0%0 after | Duplicate filing |
| Aug 19, 2021 (view filing) | Aug 17 | 2 days | Chesworth RichardChief Scientific Officer | SSale | −54.0K | $50.37 | −$2.72M | −100.0%0 after | 4 lots |
| Aug 27, 2021 (view filing) | Aug 27 | Same day | Chesworth RichardChief Scientific Officer | SSale | −33.8K | $60.12 | −$2.03M | −100.0%0 after | |
| Sep 3, 2021 (view filing) | Sep 3 | Same day | Jacobs Bruce N.Chief Financial Officer | SSale | −10.0K | $60.12 | −$601.2K | −58.0%7.26K after | 2 lots |
| Oct 12, 2021 (view filing) | Oct 8-11 | 4 days | Mainolfi NelloChief Executive Officer | SSale | −48.0K | $56.34 | −$2.70M | −9.4%464.2K after | 8 lots |
| Nov 2, 2021 (view filing) | Nov 1-2 | 1 day | Gollob JaredChief Medical Officer | SSale | −57.5K | $62.16 | −$3.57M | −70.0%24.7K after | 7 lots |
| Dec 3, 2021 (view filing) | Dec 3 | Same day | Jacobs Bruce N.Chief Financial Officer | SSale | −10.0K | $53.56 | −$535.6K | −36.3%17.5K after | 3 lots |
| Jan 12, 2022 (view filing) | Jan 10-12 | 2 days | Mainolfi NelloChief Executive Officer | SSale | −48.0K | $53.31 | −$2.56M | −9.2%472.2K after | 11 lots |
| Jan 14, 2022 (view filing) | Jan 12 | 2 days | Jacobs Bruce N.Chief Financial Officer | SSale | −15.0K | $51.84 | −$777.7K | −46.1%17.5K after | 3 lots |
| Jan 26, 2022 (view filing)7:43 PM ET | Jan 24 | 2 days | BVF Partners L P and 9 othersDirector, Other: See Remarks | PPurchaseCommon Stock, $0.0001 par value | +272.8K | $37.76 | +$10.3M | +25.5%1.34M after | 2 lots |
| Jan 31, 2022 (view filing)7:44 PM ET | Jan 27-31 | 4 days | BVF Partners L P and 9 othersDirector, Other: See Remarks | PPurchaseCommon Stock, $0.0001 par value | +130.3K | $38.96 | +$5.08M | +10.3%1.40M after | 4 lots |
| May 9, 2022 (view filing)7:20 PM ET | May 5-6 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +250.0K | $19.46 | +$4.87M | New position216.7K after | 6 lots |
| May 24, 2022 (view filing)8:09 PM ET | May 20 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +10.1K | $14.00 | +$141.4K | +4.9%216.8K after | 3 lots |
| May 31, 2022 (view filing)7:50 PM ET | May 26-27 | 5 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +289.4K | $14.34 | +$4.15M | New position230.6K after | 6 lots |
| Aug 23, 2022 (view filing)5:35 PM ET | Aug 22 | 1 day | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +545.5K | $26.00 | +$14.2M | New position257.8K after | 3 lots |
| Nov 1, 2022 (view filing) | Oct 28-Nov 1 | 4 days | Booth BruceDirector | SSale | −288.7K | $30.26 | −$8.74M | −21.6%1.05M after | 8 lots |
| Nov 1, 2022 (view filing)7:34 PM ET | Oct 28-Nov 1 | 4 days | Atlas Venture Fund X, L.P. and 5 others10% Owner | SSale | −225.6K | $30.26 | −$6.82M | −3.9%5.54M after | 4 lots |
| Nov 1, 2022 (view filing)7:34 PM ET | Oct 28-Nov 1 | 4 days | Atlas Venture Fund X, L.P. and 5 others10% Owner | SSale | −63.1K | $30.26 | −$1.91M | −5.7%1.05M after | 4 lots |
| Nov 4, 2022 (view filing) | Nov 2-3 | 2 days | Booth BruceDirector | SSale | −220.0K | $30.01 | −$6.60M | −18.0%1.00M after | 4 lots |
| Nov 4, 2022 (view filing)4:30 PM ET | Nov 2-3 | 2 days | Atlas Venture Fund X, L.P. and 5 others10% Owner | SSale | −171.9K | $30.01 | −$5.16M | −3.1%5.37M after | 2 lots |
| Nov 4, 2022 (view filing)4:30 PM ET | Nov 2-3 | 2 days | Atlas Venture Fund X, L.P. and 5 others10% Owner | SSale | −48.1K | $30.01 | −$1.44M | −4.6%1.00M after | 2 lots |
| Dec 16, 2022 (view filing) | Dec 14-15 | 2 days | Booth BruceDirector | SSale | −382.2K | $31.36 | −$12.0M | −29.4%917.8K after | 12 lots |
| Dec 16, 2022 (view filing)5:03 PM ET | Dec 14-15 | 2 days | Atlas Venture Fund X, L.P. and 5 others10% Owner | SSale | −298.6K | $31.36 | −$9.36M | −5.6%5.07M after | 6 lots |
| Dec 16, 2022 (view filing)5:03 PM ET | Dec 14-15 | 2 days | Atlas Venture Fund X, L.P. and 5 others10% Owner | SSale | −83.6K | $31.36 | −$2.62M | −8.3%917.8K after | 6 lots |
| Jan 13, 2023 (view filing) | Jan 11-12 | 2 days | Booth BruceDirector | SSale | −126.5K | $30.22 | −$3.82M | −12.4%890.1K after | 4 lots |
| Jan 13, 2023 (view filing)4:50 PM ET | Jan 11-12 | 2 days | Atlas Venture Fund X, L.P. and 5 others10% Owner | SSale | −98.8K | $30.22 | −$2.99M | −2.0%4.97M after | 2 lots |
| Jan 13, 2023 (view filing)4:50 PM ET | Jan 11-12 | 2 days | Atlas Venture Fund X, L.P. and 5 others10% Owner | SSale | −27.7K | $30.22 | −$835.9K | −3.0%890.1K after | 2 lots |
| Jan 13, 2023 (view filing)5:08 PM ET | Jan 11-12 | 2 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +41.0K | $30.51 | +$1.25M | +2.2%1.89M after | 4 lots |
| Mar 3, 2023 (view filing) | Mar 2 | 1 day | Jacobs Bruce N.Chief Financial Officer | SSale | −1.37K | $31.00 | −$42.5K | −1.3%104.6K after | 2 lots |
| Mar 3, 2023 (view filing) | Mar 2 | 1 day | Gollob JaredChief Medical Officer | SSale | −1.30K | $31.00 | −$40.2K | −1.7%74.7K after | 2 lots |
| Mar 3, 2023 (view filing) | Mar 2 | 1 day | Caughey ElaineChief Business Officer | SSale | −714 | $31.00 | −$22.1K | −3.6%19.0K after | 2 lots |
| Nov 6, 2023 (view filing)6:07 PM ET | Nov 2-3 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +414.1K | $12.80 | +$5.30M | New position294.6K after | 6 lots |
| Jan 5, 2024 (view filing) | Jan 4 | 1 day | Chiniara EllenChief Legal Officer | SSale | −3.29K | $22.58 | −$74.4K | −8.8%34.2K after | |
| Jan 9, 2024 (view filing)4:49 PM ET | Jan 5 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +979.0K | $25.25 | +$24.7M | –52.7K after | Derivative3 lots |
| Jan 23, 2024 (view filing) | Jan 23 | Same day | Albers Jeffrey W.Director | SSale | −10.0K | $30.05 | −$300.5K | −100.0%0 after | 10b5-1 |
| Feb 9, 2024 (view filing) | Feb 9 | Same day | Gollob JaredChief Medical Officer | SSale | −46.1K | $35.50 | −$1.64M | −38.2%74.7K after | 2 lots10b5-1 |
| Feb 21, 2024 (view filing) | Feb 20-21 | 1 day | Albers Jeffrey W.Director | SSale | −5.00K | $39.05 | −$195.3K | −100.0%0 after | 2 lots10b5-1 |
| Feb 29, 2024 (view filing) | Feb 27 | 2 days | Gollob JaredChief Medical Officer | SSale | −400 | $45.00 | −$18.0K | −0.5%74.7K after | 10b5-1 |
| Mar 4, 2024 (view filing) | Mar 4 | Same day | Jacobs Bruce N.Chief Financial Officer | SSale | −3.93K | $41.85 | −$164.7K | −2.7%142.4K after | 3 lots |
| Mar 4, 2024 (view filing) | Mar 4 | Same day | Gollob JaredChief Medical Officer | SSale | −3.34K | $41.85 | −$140.0K | −3.4%95.7K after | 3 lots |
| Mar 13, 2024 (view filing) | Mar 11-13 | 2 days | Booth BruceDirector | SSale | −353.4K | $42.20 | −$14.9M | −29.9%828.8K after | 12 lots10b5-1 |
| Mar 13, 2024 (view filing)7:53 PM ET | Mar 11-13 | 2 days | Atlas Venture Fund X, L.P. and 5 others10% Owner | SSale | −292.0K | $42.20 | −$12.3M | −5.9%4.68M after | 6 lots10b5-1 |
| Mar 13, 2024 (view filing)7:53 PM ET | Mar 11-13 | 2 days | Atlas Venture Fund X, L.P. and 5 others10% Owner | SSale | −61.3K | $42.20 | −$2.59M | −6.9%828.8K after | 6 lots10b5-1 |
| Mar 15, 2024 (view filing) | Mar 14-15 | 1 day | Booth BruceDirector | SSale | −127.4K | $40.25 | −$5.13M | −13.6%806.7K after | 11 lots10b5-1 |